

Fine Foods continues to produce and to ship products to customers

The intention to move to MTA is confirmed, with a timetable to be defined once overcome the extraordinary national and international situation deriving from the Covid-19 pandemic

Verdellino (BG), 4 May 2020

Fine Foods & Pharmaceuticals N.T.M. S.p.A. (the "Company") confirms that - despite the restrictive measures taken at national and international level to contain the spread of the Covid-19 pandemic - the Company continues to produce Medicinal Drugs and Health Goods (Food Supplements) and to deliver them to customers, pursuant to the Italian Legislation as detailed in the Report on Operations of the Financial Statements as of 31 December 2019.

The Company also confirms its intention to make the transition to Borsa Italiana's Main Market, MTA, albeit according to a different timeline than that originally indicated in the Prospectus relating to the merger by incorporation of Fine Foods & Pharmaceuticals N.T.M. S.p.A. in Innova Italy 1 S.p.A.. This also in order to allow the Company to continue to focus on all the current extraordinary efforts aimed to maintain its production activities and to overcome the extraordinary situation that is affecting the national and international markets, deriving from the Covid-19 pandemic. In order to make the transition to the Main Market in the best conditions, in the interest of the Company and all its Shareholders, the new timetable could be communicated only once the present situation has normalized and, hopefully, with the approval of the Half-Year Financial Report as of 30 June 2020. In the meantime, the Company intends to pursue its development objectives through the most appropriate strategic actions which may include organic growth, external growth and investments in new technologies.

This press release is available on the Fine Foods website www.finefoods.it, in the Investor relations / Press Releases section.

Fine Foods & Pharmaceuticals N.T.M. S.p.A., founded in 1984, is the leading independent Italian company in the sector of CDMOs (contract development and manufacturing organization) of solid oral forms for the pharmaceutical and nutraceutical industries. The company is recognised on the market for its high-quality products and has long-term relationships with most of its customers (more than one hundred). It has more than 600 employees and has generated revenues for about 160 million euros with over 60 per cent of its sales volumes abroad in 2019.

For information:

Fine Foods & Pharmaceuticals N.T.M. S.p.A.

Investor Relations

tel. +39 035 4821382

ir@finefoods.it

Banca Akros S.p.A.

Nomad

Viale Eginardo 29, Milan

ecm@bancaakros.it

CDR Communication

IR Advisor

Paola Buratti

paola.buratti@cdr-communication.it

Media Relations

Marianna Tremolada

marianna.tremolada@cdr-communication.it